Compare CVS Health Corp (CVS) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs State Street Technology Select Sector SPDR ETF — how do they compare? CVS Health Corp trades at $86.85 (market cap $112.29B), while State Street Technology Select Sector SPDR ETF trades at $197.91 (market cap $132.55B). The key difference: State Street Technology Select Sector SPDR ETF is the larger of the two by market cap, and CVS Health Corp pays a 3.03% dividend while State Street Technology Select Sector SPDR ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and State Street Technology Select Sector SPDR ETF for 49 Days on average.
| CVS | XLK | |
|---|---|---|
Market Cap | $112.29B | $132.55B |
Volume | 7,763,676 | 9,063,135 |
Sector | Health | Sector/Thematic |
52-Week High | $110.60 | $202.00 |
52-Week Low | $70.08 | $127.49 |
Typical Hold Time | 83 Days | 49 Days |
Enterprise Value | $174.64B | — |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
XLK, the Technology Select Sector SPDR ETF, trades at $197.73, down 1.82% amid broader tech pressure. The technical outlook is bullish based on moving averages, with support at $196 and resistance at $201. Recent news highlights concentration risks in semiconductor holdings and competition from thematic AI ETFs.
The ETF faces headwinds from potential Fed rate hikes and sector rotation but benefits from strong AI investment themes. Risks include overconcentration in mega-cap tech and interest rate sensitivity, while its low expense ratio and diversified tech exposure offer a defensive growth play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
